News | October 13, 2021
PCI Pharma Services acquires LSNE for its CDMO business
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
The drug is being developed at lab scale for the first-line of treatment of Covid-19
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Subscribe To Our Newsletter & Stay Updated
